Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Feb. 2026,
Cannabis Bioscience International Holdings paid$0.00 Mil more to buy back shares than it received from issuing new shares.
It received$0.02 Mil from issuing more debt.
It paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0.00 Mil from paying cash dividends to shareholders.
It received$0.00 Mil on other financial activities.
In all, Cannabis Bioscience International Holdingsearned$0.02 Mil on financial activities for the
three
months ended in Feb. 2026.
Cannabis Bioscience International Holdings (OTCPK:CBIH) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Cannabis Bioscience International Holdings's issuance of stock for the
three
months ended in Feb. 2026 was $0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Cannabis Bioscience International Holdings's repurchase of stock for the
three
months ended in Feb. 2026 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Cannabis Bioscience International Holdings's net issuance of debt for the
three
months ended in Feb. 2026 was $0.02 Mil.
Cannabis Bioscience International Holdings received$0.02 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Cannabis Bioscience International Holdings's net issuance of preferred for the
three
months ended in Feb. 2026 was $0.00 Mil.
Cannabis Bioscience International Holdings paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cannabis Bioscience International Holdings's cash flow for dividends for the
three
months ended in Feb. 2026 was $0.00 Mil.
Cannabis Bioscience International Holdings received$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Cannabis Bioscience International Holdings's other financing for the
three
months ended in Feb. 2026 was $0.00 Mil.
Cannabis Bioscience International Holdings received$0.00 Mil on other financial activities.
Cannabis Bioscience International Holdings Cash Flow from Financing Related Terms
Cannabis Bioscience International Holdings Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabis Bioscience International Holdings Cash Flow from Financing Chart
Cannabis Bioscience International Holdings Annual Data
Cannabis Bioscience International Holdings Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $0.27 Mil mean?
Cannabis Bioscience International Holdings (CBIH) has a Cash Flow from Financing of $0.27 Mil as of Feb. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Cannabis Bioscience International Holdings and its competitors.
Is Cannabis Bioscience International Holdings' Cash Flow from Financing too high?
Cannabis Bioscience International Holdings' current Cash Flow from Financing is $0.27 Mil.
How does Cannabis Bioscience International Holdings' Cash Flow from Financing compare to SXTC and UPC?
Cannabis Bioscience International Holdings' Cash Flow from Financing of $0.27 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Cannabis Bioscience International Holdings and its competitors. Cannabis Bioscience International Holdings's current Cash Flow from Financing is $0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Bioscience International Holdings stock overvalued right now?
Cannabis Bioscience International Holdings (CBIH) has a current Cash Flow from Financing of $0.27 Mil. The current Cash Flow from Financing is $0.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Cannabis Bioscience International Holdings (CBIH), the current Cash Flow from Financing is $0.27 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cannabis Bioscience International Holdings Inc operates in three main areas. Firstly, the company engages in cannabis-related research and education under the trade name Pharmacology University. Secondly, it serves as both a Sponsor and a Contract Research Organization (CRO) in clinical trials, some of which involve cannabis and CBD products, under the trade name Alpha Research Institute. Lastly, the company plans to manufacture, market, and sell CBD products branded as "VitaCookies." The majority of the company's revenue comes from clinical trial contracts, while a smaller portion is generated from cannabis-related educational classes and seminars.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIH has been successfully added to your 
